Nothing Special   »   [go: up one dir, main page]

SG10201801658XA - Methods and compositions for rna-guided treatment of hiv infection - Google Patents

Methods and compositions for rna-guided treatment of hiv infection

Info

Publication number
SG10201801658XA
SG10201801658XA SG10201801658XA SG10201801658XA SG10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA SG 10201801658X A SG10201801658X A SG 10201801658XA
Authority
SG
Singapore
Prior art keywords
rna
compositions
methods
hiv infection
guided treatment
Prior art date
Application number
SG10201801658XA
Other languages
English (en)
Inventor
Kamel Khalili
Wenhui Hu
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of SG10201801658XA publication Critical patent/SG10201801658XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
SG10201801658XA 2013-08-29 2014-08-29 Methods and compositions for rna-guided treatment of hiv infection SG10201801658XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871626P 2013-08-29 2013-08-29
US201462018441P 2014-06-27 2014-06-27
US201462026103P 2014-07-18 2014-07-18

Publications (1)

Publication Number Publication Date
SG10201801658XA true SG10201801658XA (en) 2018-03-28

Family

ID=52587370

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201801658XA SG10201801658XA (en) 2013-08-29 2014-08-29 Methods and compositions for rna-guided treatment of hiv infection
SG11201601313TA SG11201601313TA (en) 2013-08-29 2014-08-29 Methods and compositions for rna-guided treatment of hiv infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601313TA SG11201601313TA (en) 2013-08-29 2014-08-29 Methods and compositions for rna-guided treatment of hiv infection

Country Status (15)

Country Link
US (24) US9925248B2 (zh)
EP (2) EP4385567A3 (zh)
JP (3) JP7118588B2 (zh)
KR (2) KR20160060659A (zh)
CN (1) CN106102781A (zh)
AU (2) AU2014312123A1 (zh)
BR (1) BR112016004091A2 (zh)
CA (1) CA2922428A1 (zh)
CL (1) CL2016000424A1 (zh)
EA (1) EA037850B1 (zh)
IL (1) IL244220B (zh)
MX (1) MX2016002586A (zh)
SG (2) SG10201801658XA (zh)
WO (1) WO2015031775A1 (zh)
ZA (1) ZA201601344B (zh)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012333134B2 (en) 2011-07-22 2017-05-25 John Paul Guilinger Evaluation and improvement of nuclease cleavage specificity
EP3327127B1 (en) 2012-12-12 2021-03-24 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP3434776A1 (en) 2012-12-12 2019-01-30 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP4428141A2 (en) 2013-03-15 2024-09-11 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
SG11201510286QA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
KR20160044457A (ko) 2013-06-17 2016-04-25 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화
JP6738728B2 (ja) 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CN106102781A (zh) 2013-08-29 2016-11-09 英联邦高等教育系统天普大学 用于hiv感染的rna指导的治疗的方法和组合物
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
CN118813621A (zh) 2013-12-12 2024-10-22 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
CN106029880A (zh) 2013-12-12 2016-10-12 布罗德研究所有限公司 核苷酸重复障碍中CRISPR-Cas系统的组合物和使用方法
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2932479A1 (en) * 2013-12-12 2015-06-18 The Rockefeller University Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
BR112016019068A2 (pt) * 2014-02-18 2017-10-10 Univ Duke construto, vetor recombinante, composição farmacêutica, método de inibição de replicação viral ou expressão de uma sequência alvo em uma célula infectada com um vírus, polipeptídeo de sau cas9 recombinante, construto de sau cas9 recombinante, construto recombinante para expressão de um rna guia individual e kit
EP3149169A1 (en) 2014-05-30 2017-04-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
AU2015277369B2 (en) 2014-06-16 2021-08-19 The Johns Hopkins University Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
MX2017004890A (es) 2014-10-15 2018-02-12 Regeneron Pharma Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
PL3221457T3 (pl) 2014-11-21 2019-09-30 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do celowanej modyfikacji genetycznej z zastosowaniem sparowanych przewodników RNA
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
MA41382A (fr) * 2015-03-20 2017-11-28 Univ Temple Édition génique basée sur le système crispr/endonucléase à induction par tat
CN104726449A (zh) * 2015-03-23 2015-06-24 国家纳米科学中心 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途
WO2016161260A1 (en) * 2015-04-02 2016-10-06 Agenovir Corporation Gene delivery methods and compositions
EP3294343A4 (en) * 2015-05-13 2018-09-26 Seattle Children's Hospital, dba Seattle Children's Research Institute Enhancing endonuclease based gene editing in primary cells
JP2018516984A (ja) * 2015-05-29 2018-06-28 アジェノビア コーポレーション 細胞を標的にしたｈｐｖ処置のための組成物および方法
WO2016196283A1 (en) * 2015-05-29 2016-12-08 Agenovir Corporation Antiviral methods and compositions
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US11298410B2 (en) * 2015-06-01 2022-04-12 Temple University—Of the Commonwealth System of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
CN104894071A (zh) * 2015-06-08 2015-09-09 东华大学 一种对gt1-7细胞进行基因编辑的方法
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
IL284808B (en) 2015-06-18 2022-07-01 Broad Inst Inc Mutations in the crispr enzyme that reduce unintended effects
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN114875012A (zh) 2015-08-28 2022-08-09 通用医疗公司 工程化的CRISPR-Cas9核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
AU2016332345A1 (en) * 2015-09-28 2018-04-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US20170096649A1 (en) * 2015-10-02 2017-04-06 Agenovir Corporation Transgenic nuclease systems and methods
CN116064664A (zh) 2015-10-08 2023-05-05 哈佛学院董事及会员团体 多重基因组编辑
JP2018531261A (ja) * 2015-10-16 2018-10-25 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Ｃｐｆ１を用いた、ｒｎａガイド遺伝子編集方法および組成物
IL310721A (en) 2015-10-23 2024-04-01 Harvard College Nucleobase editors and their uses
EP3387001A4 (en) 2015-12-09 2019-08-14 Excision Biotherapeutics, Inc. METHODS AND COMPOSITIONS OF GENE EDITION TO ELIMINATE THE RISK OF ACTIVATING JC VIRUS AND PML (PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY) DURING IMMUNOSUPPRESSE TREATMENT
AU2017211062A1 (en) * 2016-01-25 2018-06-07 Excision Biotherapeutics Methods and compositions for RNA-guided treatment of HIV infection
AU2017219605B2 (en) * 2016-02-15 2023-04-13 Temple University - Of The Commonwealth System Of Higher Education Excision of retroviral nucleic acid sequences
CN114908093A (zh) * 2016-02-26 2022-08-16 朗泽科技新西兰有限公司 用于c1固定菌的crispr/cas系统
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
JP2019519250A (ja) * 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズＵｎｉｔｅｄ Ｓｔａｔｅｓ Ｇｏｖｅｒｎｍｅｎｔ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｄｅｐａｒｔｍｅｎｔ Ｏｆ Ｖｅｔｅｒａｎｓ Ａｆｆａｉｒｓ Ｈｉｖ−１感染と複製に必須な遺伝子を切断するｃｒｉｓｐｒ／ｃａｓの構築物のレンチウィルスによる送達
CN107365786A (zh) * 2016-05-12 2017-11-21 中国科学院微生物研究所 一种将spacer序列克隆至CRISPR-Cas9系统中的方法及其应用
CN109069560A (zh) * 2016-06-01 2018-12-21 切除生物治疗公司 用于裂解性病毒和溶原性病毒的组合物和治疗方法
RU2018144877A (ru) * 2016-06-03 2020-07-09 Темпл Юниверсити - Оф Де Коммонвелт Систем Оф Хаер Эдьюкейшн Регуляция HIV-1 по механизму отрицательной обратной связи с помощью стратегии редактирования генов
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nuclear base editors and their uses
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP2019536428A (ja) * 2016-09-12 2019-12-19 エクシジョン バイオセラピューティクス インコーポレイテッド Ｈｉｖ臨床計画
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018070850A1 (ko) * 2016-10-14 2018-04-19 연세대학교 산학협력단 Kras 유전자에 상보적인 가이드 rna 및 이의 용도
KR101997116B1 (ko) 2016-10-14 2019-07-05 연세대학교 산학협력단 Kras 유전자에 상보적인 가이드 rna 및 이의 용도
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US20190071673A1 (en) * 2017-01-18 2019-03-07 Thomas Malcolm CRISPRs WITH IMPROVED SPECIFICITY
WO2018152418A1 (en) * 2017-02-17 2018-08-23 Temple University - Of The Commonwealth System Of Higher Education Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CN106755268B (zh) * 2017-03-22 2020-07-17 中国科学院海洋研究所 体外筛选具有改善记忆力的牡蛎活性肽的方法
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018194876A1 (en) * 2017-04-17 2018-10-25 Temple University- Of The Commonwealth System Of Higher Education An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
SG11201909797QA (en) 2017-04-20 2019-11-28 Egenesis Inc Methods for generating genetically modified animals
AU2018254619B2 (en) 2017-04-21 2022-07-21 The General Hospital Corporation Variants of Cpf1 (CAS12a) with altered PAM specificity
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CA3064828A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
WO2019079819A1 (en) * 2017-10-20 2019-04-25 City Of Hope COMPOSITION AND METHOD FOR ACTIVATION OF LATENT HUMAN IMMUNODEFICIENCY VIRUS (HIV)
US20220194990A1 (en) * 2019-01-31 2022-06-23 Board Of Regents Of The University Of Nebraska Virus-like particles and methods of use thereof
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
KR20220030945A (ko) 2019-05-23 2022-03-11 크리스티아나 케어 헬스 서비시즈 인코포레이티드 암의 치료를 위한 nrf2의 유전자 녹아웃
KR20220018504A (ko) 2019-05-23 2022-02-15 크리스티아나 케어 헬스 서비시즈 인코포레이티드 암 치료를 위한 변이체 nrf2의 유전자 녹아웃
CN115867650A (zh) 2020-04-20 2023-03-28 克里斯蒂安娜基因编辑研究公司 用于肺癌治疗的aav递送系统
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CA3185970A1 (en) * 2020-07-13 2022-01-20 Alexandra L. Howell Methods and compositions for crispr/cas9 guide rna efficiency and specificity against genetically diverse hiv-1 isolates
EP4256044A1 (en) * 2020-12-01 2023-10-11 United States Government as Represented by The Department of Veterans Affairs Compositions and methods for cleaving viral genomes
AU2022216614A1 (en) 2021-02-05 2023-02-23 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
AU2022393213A1 (en) 2021-11-19 2024-05-30 Christiana Care Gene Editing Institute, Inc. Methods for intratumoral delivery of crispr/cas systems
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023154451A1 (en) 2022-02-10 2023-08-17 Christiana Care Gene Editing Institute, Inc. Methods for lipid nanoparticle delivery of crispr/cas system
CN114657185B (zh) * 2022-03-28 2023-11-10 福州大学 一种基于适配体有序排列的金磁纳米探针及其在大田软海绵酸检测中的应用
CN115762764A (zh) * 2022-11-25 2023-03-07 中山大学附属第三医院 一种hiv阴性隐球菌脑膜炎治疗结局预测模型及其构建方法
WO2024130151A1 (en) 2022-12-16 2024-06-20 Christiana Care Gene Editing Institute, Inc. Compositions and methods for treating broad chemoresistance through chemoresistance-specific regulatory components

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
TW247876B (en) 1993-12-28 1995-05-21 New York Blood Ct Inc Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
WO1997037005A1 (en) * 1996-04-02 1997-10-09 Progenics Pharmaceuticals, Inc. Method for preventing hiv-1 infection of cd4+ cells
US6392029B1 (en) * 1997-05-09 2002-05-21 The Research Foundation Of State University Of New York HIV chemokines
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
ATE528406T1 (de) * 1999-04-29 2011-10-15 Gbp Ip Llc Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
FR2825280B1 (fr) 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
US20030180756A1 (en) 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
US20070175484A1 (en) 2006-01-30 2007-08-02 Staab Robert J Condoms for beneficial agents delivery
EP1942192A1 (en) 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Use of a tailored recombinase for the treatment of retroviral infections
CN103060378A (zh) 2011-10-24 2013-04-24 四川百利药业有限责任公司 一种siv载体的制备方法
GB201122458D0 (en) * 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CN113355357A (zh) 2012-12-12 2021-09-07 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP3327127B1 (en) 2012-12-12 2021-03-24 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
SG11201504621RA (en) 2012-12-17 2015-07-30 Harvard College Rna-guided human genome engineering
ES2747833T3 (es) * 2013-04-04 2020-03-11 Dartmouth College Composiciones y procedimientos para la escisión in vivo del ADN proviral del vih-1
CN106102781A (zh) 2013-08-29 2016-11-09 英联邦高等教育系统天普大学 用于hiv感染的rna指导的治疗的方法和组合物
EP3149169A1 (en) * 2014-05-30 2017-04-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods of delivering treatments for latent viral infections
US11298410B2 (en) 2015-06-01 2022-04-12 Temple University—Of the Commonwealth System of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
AU2016332345A1 (en) 2015-09-28 2018-04-12 Temple University - Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
JP2018531261A (ja) 2015-10-16 2018-10-25 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Ｃｐｆ１を用いた、ｒｎａガイド遺伝子編集方法および組成物
EP3387001A4 (en) 2015-12-09 2019-08-14 Excision Biotherapeutics, Inc. METHODS AND COMPOSITIONS OF GENE EDITION TO ELIMINATE THE RISK OF ACTIVATING JC VIRUS AND PML (PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY) DURING IMMUNOSUPPRESSE TREATMENT
WO2018106268A1 (en) 2016-01-25 2018-06-14 Excision Biotherapeutics Rna guided eradication of human jc virus and other polyomaviruses
AU2017211062A1 (en) 2016-01-25 2018-06-07 Excision Biotherapeutics Methods and compositions for RNA-guided treatment of HIV infection
AU2017219605B2 (en) 2016-02-15 2023-04-13 Temple University - Of The Commonwealth System Of Higher Education Excision of retroviral nucleic acid sequences
US20190093091A1 (en) 2016-04-06 2019-03-28 Temple University - Of The Commonwealth System Of Higher Education Compositions for eradicating flavivirus infections in subjects
WO2017192172A1 (en) 2016-05-05 2017-11-09 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of varicella zoster virus
CN109565871B (zh) 2016-05-26 2022-03-11 诺基亚技术有限公司 用于非正交编码接入的码字自适应
US20190256844A1 (en) 2016-06-07 2019-08-22 Temple University - Of The Commonwealth System Of Higher Education Rna guided compositions for preventing and treating hepatitis b virus infections
US20190085326A1 (en) 2016-09-14 2019-03-21 Temple University - Of The Commonwealth System Of Higher Education Negative feedback regulation of HIV-1 by gene editing strategy
US20190365862A1 (en) 2016-10-12 2019-12-05 Temple University - Of The Commonwealth System Of Higher Education Combination therapies for eradicating flavivirus infections in subjects
CN110431230A (zh) 2017-01-26 2019-11-08 切除生物治疗公司 慢病毒和非整合型慢病毒作为病毒载体实施crispr治疗
WO2018152418A1 (en) 2017-02-17 2018-08-23 Temple University - Of The Commonwealth System Of Higher Education Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
WO2018194876A1 (en) 2017-04-17 2018-10-25 Temple University- Of The Commonwealth System Of Higher Education An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
US20210060138A1 (en) 2019-03-06 2021-03-04 Temple University - Of The Commonwealth System Of Higher Education CRISPR and LASER ART Eliminates HIV

Also Published As

Publication number Publication date
KR20160060659A (ko) 2016-05-30
MX2016002586A (es) 2016-06-14
US20180169195A1 (en) 2018-06-21
JP2020188757A (ja) 2020-11-26
CL2016000424A1 (es) 2017-07-14
US20180228875A1 (en) 2018-08-16
US9925248B2 (en) 2018-03-27
US20180221458A1 (en) 2018-08-09
EP4385567A2 (en) 2024-06-19
US20180200343A1 (en) 2018-07-19
US20180236045A1 (en) 2018-08-23
CN106102781A (zh) 2016-11-09
US20180228874A1 (en) 2018-08-16
JP2023071897A (ja) 2023-05-23
IL244220A0 (en) 2016-04-21
US20180228876A1 (en) 2018-08-16
IL244220B (en) 2020-06-30
AU2020264257B2 (en) 2022-10-20
US20160250300A1 (en) 2016-09-01
US20180236043A1 (en) 2018-08-23
US20180169193A1 (en) 2018-06-21
AU2014312123A1 (en) 2016-03-17
AU2020264257A1 (en) 2020-11-26
CA2922428A1 (en) 2015-03-05
US20180214521A1 (en) 2018-08-02
US11291710B2 (en) 2022-04-05
US20230181698A1 (en) 2023-06-15
US11285193B2 (en) 2022-03-29
SG11201601313TA (en) 2016-03-30
EP3038661B1 (en) 2023-12-27
JP7118588B2 (ja) 2022-08-16
KR20230017364A (ko) 2023-02-03
US20210069303A1 (en) 2021-03-11
JP2016534125A (ja) 2016-11-04
US20180236046A1 (en) 2018-08-23
US20210252114A1 (en) 2021-08-19
US20180169194A1 (en) 2018-06-21
WO2015031775A1 (en) 2015-03-05
US20180236041A1 (en) 2018-08-23
US9981020B2 (en) 2018-05-29
EA201600226A1 (ru) 2016-09-30
US20180303915A1 (en) 2018-10-25
EP3038661A1 (en) 2016-07-06
US20180207243A1 (en) 2018-07-26
US20180236044A1 (en) 2018-08-23
BR112016004091A2 (pt) 2017-10-17
US20160017301A1 (en) 2016-01-21
ZA201601344B (en) 2017-05-31
US11298411B2 (en) 2022-04-12
US20220313795A1 (en) 2022-10-06
EP3038661A4 (en) 2017-04-05
US20180236042A1 (en) 2018-08-23
US20240139294A1 (en) 2024-05-02
EP4385567A3 (en) 2024-08-14
EA037850B1 (ru) 2021-05-27

Similar Documents

Publication Publication Date Title
ZA201601344B (en) Methods and compositions for rna-guided treatment of hiv infection
HK1253882A1 (zh) 用於hiv感染的rna導向治療的方法和組合物
EP3356521A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
HK1220935A1 (zh) 治療乙型肝炎病毒感染的方法和藥物組合物
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
HK1210022A1 (zh) 治療乙型肝炎及丁型肝炎感染的方法
HK1224210A1 (zh) 用於治療纖維化的方法和組合物
HRP20181582T1 (hr) Formulacija atazanavira i kobicistata za liječenje hiv-a
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2969006A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFECTION WITH IMMUNODEFICIENCY VIRUSES
EP2931040A4 (en) METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS
EP2968127A4 (en) LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment